Great Lakes Pharmaceuticals, Inc. is a clinical stage company organized around products designed to prevent infections associated with indwelling catheters. The firm's first product, B-Lockâ¢, is an anti-coagulant catheter lock solution with strong, broad spectrum activity against bacterial and fungal microorganisms known to form biofilm structures in indwelling catheters. The growing numbers of Bacterial and fungal infections significantly contribute to morbidity and mortality as well as to the increased cost of hospital care. Most of the hospital-acquired bacterial and fungal infections result from invasive supportive measures such as the placement of catheters. These conditions - referred to as catheter-related bloodstream infection (CRBI) - are difficult to prevent due to formation of biofilm in the catheter lumen. Great Lakes Pharmaceuticals acquired exclusive license to antibiofilm technology from University of Texas M.D. Anderson Cancer Center and Wake Forest University. Based on the licensed technology, the company has developed device/drug combination product, B-Lockâ¢, capable of effective prevention of CRBI. In addition to its antimicrobial value, B-Lock⢠solution has added benefit of antithrombotic properties. B-Lockâ¢'s spectrum of antimicrobial activity includes all bacterial and fungal pathogens associated with CRBI. Antithrombotic effectiveness equals heparin. With the use of B-Lockâ¢, there is no need for application of heparin lock so
